<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03125070</url>
  </required_header>
  <id_info>
    <org_study_id>9819</org_study_id>
    <secondary_id>NCI-2017-00583</secondary_id>
    <secondary_id>9819</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT03125070</nct_id>
  </id_info>
  <brief_title>Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant</brief_title>
  <official_title>INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-management Program for Survivors After Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase III trial studies health informatics and a self-management program in
      improving the health of cancer survivors after stem cell transplant. After transplant many
      survivors may feel stressed or may be unsure of what health care they need as a transplant
      survivor. A self-management program called &quot;INSPIRE,&quot; along with a personalized survivorship
      care plan may improve stress and health care for transplant survivors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine whether 2-5 year hematopoietic cell transplant (HCT) survivors with elevated
      cancer-related distress or poor health care adherence, adherence to cardiometabolic or
      subsequent malignancy surveillance who are randomized to receive the online,
      patient-centered, self-management stepped care program will report reduced distress, and
      improved health care adherence for cardiometabolic or subsequent malignancy surveillance at
      12 months when compared with an active control group who receive access to HCT survivorship
      best practices.

      II. Determine characteristics of intervention participants who require telehealth stepped
      care at 1-month, because they 1) do not meet criteria for adequate knowledge of subsequent
      malignancy and cardiometabolic risks, or 2) do not report improved distress, or 3) have not
      logged in to the online program.

      III. Determine resources that would be needed to sustain the intervention as a national HCT
      survivorship program if implemented through the Center for International Blood and Marrow
      Transplant Research (CIBMTR)/National Marrow Donor Program (NMDP).

      SECONDARY OBJECTIVES:

      I. Process measures of internet study reach and utilization, as well as depression, physical
      function, physical activity level, and knowledge of survivorship needs in HCT survivors.

      OUTLINE: Patients are randomized to 1 of 2 groups.

      GROUP I: Patients receive immediate access to the INSPIRE online program and personalized
      survivorship care plan.

      GROUP II: Patients receive an online program linking to existing online survivor resources
      and a personalized survivorship care plan. Patients may receive access to the INSPIRE online
      program after 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cancer and Treatment Distress (CTXD)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assesses distress or worry level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Care Adherence (HCA)-cardio</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assesses adherence to cardiometabolic surveillance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCA-cancer</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assesses adherence to subsequent malignancy surveillance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reach of web-based intervention</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Rates of participants approached vs. registering</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Utilization of web-based intervention</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by number of visits to the site, number of pages viewed, types of modalities used, attrition rates and support requests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PHQ-8 Depression</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS Physical function</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by Patient Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Godin Leisure Time Physical activity level</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by patient questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge of survivorship needs</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Assessed by patient questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2650</enrollment>
  <condition>Cancer Survivor</condition>
  <condition>Hematopoietic Cell Transplantation Recipient</condition>
  <arm_group>
    <arm_group_label>Group I (INSPIRE, survivorship care plan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive immediate access to the INSPIRE online program and personalized survivorship care plan.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (usual care)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive an online program linking to existing online survivor resources and a personalized survivorship care plan. Patients may receive access to the INSPIRE online program after 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Practice</intervention_name>
    <description>Receive usual care</description>
    <arm_group_label>Group II (usual care)</arm_group_label>
    <other_name>standard of care</other_name>
    <other_name>standard therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Internet-Based Intervention</intervention_name>
    <description>Receive INSPIRE and survivorship care plan</description>
    <arm_group_label>Group I (INSPIRE, survivorship care plan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (INSPIRE, survivorship care plan)</arm_group_label>
    <arm_group_label>Group II (usual care)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Received &gt;= 1 autologous or allogeneic (related or unrelated) HCT with curative intent
             at a participating transplant center for a hematologic malignancy

          -  Survival 2-5 years after last HCT when first approached for enrollment

          -  In remission at time of study entry, may be receiving chemoprevention

          -  English proficiency (written and spoken)

        Exclusion Criteria:

          -  Development of invasive subsequent malignancy after HCT other than non-melanoma skin
             cancer

          -  Medical or other issue prohibiting computer use, reading or ability to comply with all
             study procedures (e.g., significant vision or cognitive impairment, major illness,
             hospitalization)

          -  Lack of internet and email access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Syrjala</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heather Jim</last_name>
      <phone>813-745-6369</phone>
      <email>heather.jim@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Heather Jim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick J. Stiff</last_name>
      <phone>813-745-6369</phone>
      <email>pstiff@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick J. Stiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph P. McGuirk</last_name>
      <phone>913-588-5000</phone>
      <email>jmcguirk@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph P. McGuirk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Areej El-Jawahri</last_name>
      <phone>617-726-6369</phone>
      <email>areej_el-jawahri@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Areej El-Jawahri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph P. Uberti</last_name>
      <phone>313-576-8760</phone>
      <email>ubertij@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Joseph P. Uberti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Marrow Donor Program</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Linda J. Burns</last_name>
      <phone>612-460-4273</phone>
      <email>lburns2@nmdp.org</email>
    </contact>
    <investigator>
      <last_name>Linda J. Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for International Blood and Marrow Transplant Research</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55413-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bronwen E. Shaw</last_name>
      <phone>414-805-0700</phone>
      <email>beshaw@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Bronwen E. Shaw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shernan G. Holtan</last_name>
      <phone>402-559-6210</phone>
      <email>sghotlan@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Shernan G. Holtan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Theresa Hahn</last_name>
      <phone>877-275-7724</phone>
      <email>Theresa.hahn@Rosswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Theresa Hahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>William A Wood Jr</last_name>
      <phone>919-843-6517</phone>
      <email>wawood@email.unc.edu</email>
    </contact>
    <investigator>
      <last_name>William A Wood Jr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Navneet S. Majhail</last_name>
      <phone>216-444-2199</phone>
      <email>majhain@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Navneet S. Majhail</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alison W. Loren</last_name>
      <phone>215-615-3138</phone>
      <email>Alison.Loren@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Alison W. Loren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology at Baylor Charles A Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jana Reynolds</last_name>
      <phone>214-370-1500</phone>
      <email>jana.reynolds@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Jana Reynolds</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen L. Syrjala</last_name>
      <phone>206-667-4579</phone>
      <email>ksyrjala@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Karen L. Syrjala</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2017</study_first_submitted>
  <study_first_submitted_qc>April 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

